Skip to Content

2012 Agenda

Second International Conference on Cancer and the Heart
November 9-10, 2012

Conference Location:
MD Anderson Cancer Center
Cancer Prevention Building (CPB)
1155 Pressler Street, Floor 8
Houston, Texas 77030

PRELIMINARY AGENDA

Friday, November 9, 2012

7:00 a.mRegistration and continental breakfast

Overview
8:00-8:05 a.m.

 

Edward T.H. Yeh, M.D.
Chair, Cardiology
The University of Texas MD Anderson Cancer Center
Houston, TX

Welcome
8:05-8:15 a.m.

 

Ronald A. DePinho, M.D.,
President
MD Anderson Cancer Center
Houston, TX
Session I
8:15-8:30 a.m.
The Collaboration between Oncology and Cardiology
Moderator: Edward T.H. Yeh, M.D.
Chair, Cardiology
The University of Texas MD Anderson Cancer Center
Houston, TX
 ASCO
Sandra Swain, M.D.
President, ASCO
Medical Director, Washington Cancer Institute
Washington, D.C.
 ACC
William A. Zoghbi, M.D.
President, American College of Cardiology
The Methodist DeBakey Heart & Vascular Center
Houston, TX
Session II
8:30-9:30 a.m.
Advances in Cardiology and Oncology
Moderator: Edward T.H. Yeh, M.D.
The University of Texas MD Anderson Cancer Center
Houston, TX

8:30-9:00 a.m.

 

MicroRNA control of cardiac disease and repair
Eric Olson, Ph.D.
UT Southwestern Medical Center at Dallas
Dallas, TX

9:00-9:30 a.m.

 

 

Changing landscape of cancer research and care
Edward J. Benz, Jr., M.D.
President and CEO
Dana-Farber Cancer Institute
Boston, MA  
Break9:30-9:50 a.m.
Session III
9:50-10:55 a.m.
Anthracycline-induced cardiotoxicity
Moderator: Gabriel N. Hortobagyi, M.D.
The University of Texas MD Anderson Cancer Center
Houston, TX

9:50-10:15 a.m.

 

 

Molecular basis of Doxorubicin-induced cardiotoxicity
Edward T.H. Yeh, M.D.
Chair, Cardiology
The University of Texas MD Anderson Cancer Center
Houston, TX

10:15-10:35 a.m.

 

 

The evolving role of anthracyclines in the treatment of breast cancer
Gabriel N. Hortobagyi, M.D.
The University of Texas MD Anderson Cancer Center
Houston, TX
10:35-10:55 a.m.Panel discussion
Robert S. Benjamin, M.D.
Chair, Sarcoma Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX

Steven Lipshultz, M.D.
University of Miami Miller School of Medicine
Miami, FL

Edward T.H. Yeh, M.D.
Chair, Cardiology
The University of Texas MD Anderson Cancer Center
Houston, TX
Session IV
10:55-11:40 a.m.
Herceptin-induced cardiotoxicity
Moderator: Vincent Valero, M.D.
Professor and Chair Ad Interim
Breast Medical Oncology
The University of Texas M. D. Anderson Cancer Center
Houston, TX

10:55-11:25 a.m.

 


Cardiotoxicity with HER2 targeted therapy
Sandra Swain, M.D.
President, ASCO
Medical Director, Washington Cancer Institute
Washington, D.C.

11:25-11:40 a.m.

 

Trastuzumab: Guilty or guilty by association
Michael Ewer, M.D., J.D., M.P.H.
The University of Texas MD Anderson Cancer Center
Houston, TX
Lunch11:40-12:55 p.m
Session V
12:00-12:35 p.m.
Onco-cardiology services

12:00-12:05 p.m.

 

 

Introduction
Robert F. Gagel, M.D.
Division Head, Division of Internal Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
12:05-12:35 p.m.Moderator: Richard Steingart, M.D.
Memorial Sloan-Kettering Cancer Center
New York, NY
 Ana Barac, M.D., Ph.D.
Medstar Heart Institute
Washington Cancer Institute
Washington, D.C.
 Steven M. Ewer, M.D.
School Of Medicine and Public Health
University Of Wisconsin-Madison
Madison, WI
 Kerry Russell, M.D., Ph.D.
Yale University Medical School
New Haven, CT
 Edward T.H. Yeh, M.D.
Chair, Cardiology
The University of Texas MD Anderson Cancer Center
Houston, TX
12:35-12:55Break
Session VI
12:55-1:35 p.m.
Basic mechanisms
Moderator: Raymond Russell, M.D., Ph.D.
Yale University Medical School
New Haven, CT

12:55-1:15 p.m.

 

 

Chemical biology approaches to chemotherapy cardiotoxicity: Fighting fire with fire
Jay Schneider, M.D., Ph.D.
UT Southwestern Medical Center at Dallas
Dallas, TX

1:15-1:35 p.m.

 

Chemotherapy and cardiomyocyte autophagy
Joseph A. Hill, M.D., Ph.D.
UT Southwestern Medical Center at Dallas
Dallas, TX
Session VII
1:35-2:25 p.m.
Cardiotoxicity in pediatric populations
Moderator:  Joann L Ater, M.D.
The University of Texas MD Anderson Cancer Center
Houston, TX

1:35-2:00 p.m.

 

Childhood cancer cardiovascular toxicity
Steven E. Lipshultz, M.D.
University of Miami Miller School of Medicine
Miami, FL

2:00-2:15 p.m.

 

 

Cardiotoxicity in aging adult survivors of childhood cancer
Gregory T. Armstrong, M.D., M.S.C.E.
St. Jude Children's Research Hospital
Memphis, TN
2:15-2:25 p.m.Questions and answers
Break2:25-2:45 p.m.
Session VIII
2:45-3:30 p.m.
Early identification of patients with heart failure: Biomarkers
Moderator: Michael Fisch, M.D.
The University of Texas MD Anderson Cancer Center
Houston, TX

2:45-3:05 p.m.

 

 

Evolution of biomarkers in detecting early cardiac damage
Daniela Cardinale, M.D., Ph.D.
European Institute of Oncology
Milano, Italy

3:05-3:20 p.m.

 

PREDICT study
Daniel Lenihan, M.D.
Vanderbilt University Medical Center
Nashville, TN
3:20-3:30 p.m.Questions and answers
Session IX
3:30-5:00 p.m.
Early identification of patients with heart failure: Echo and MRI
Moderator: Jose Banchs, M.D.
The University of Texas MD Anderson Cancer Center
Houston, TX

3:30-3:55 p.m.

 

Early identification of patients with cardiac complications of chemotherapy
Thomas Marwick, M.D., Ph.D., M.P.H.
Menzies Research Institute of Tasmania
Hobart, Australia

3:55-4:20 p.m.

 

Cardiovascular injury upon receipt of chemotherapy- New insights from magnetic resonance imaging
W. Gregory Hundley, M.D.
Wake Forest University Baptist Medical Center
Winston-Salem, NC
4:20-4:35 p.m.Advanced echocardiography in the evaluation of chemotherapy patients
Juan Carlos Plana, M.D.
Cleveland Clinic
Cleveland, OH
4:35-4:45 p.mCase presentation
Jose Banchs, M.D.
The University of Texas MD Anderson Cancer Center
Houston, TX
4:45-5:00 p.m.Questions and answers
Session X
5:00-6:00 p.m.
Poster Session: Beer, Wine, and Hors D'oeurves

Saturday, November 10, 2012

7:00 a.mRegistration and continental breakfast
Session XI
8:00-8:45 a.m.
Radiation
Moderator: S. Wamique Yusuf, M.D.
The University of Texas MD Anderson Cancer Center
Houston, TX

8:00-8:10 a.m.

 

Case presentation
S. Wamique Yusuf, M.D.
The University of Texas MD Anderson Cancer Center
Houston, TX

8:10-8:35 a.m.

 

Radiation-related heart disease: How big are the risks?
Sarah Darby, Ph.D.
University of Oxford
Oxford, United Kingdom
8:35-8:45 a.m.Questions and answers
Session XII
8:45-10:05 a.m.
Cardiotoxicity of TKIs
Moderator: Edward T.H. Yeh, M.D.
Cardiology
The University of Texas MD Anderson Cancer Center
Houston, TX

8:45-9:05 a.m.


Why is preclinical prediction of cardiotoxicity so bad?
Thomas Force, M.D.
Temple University School of Medicine
Philadelphia, PA

9:05-9:20 a.m.

 

Tyrosine Kinase Inhibitors Related Cardiotoxicity: Is there a role for routine cardiac monitoring?
Elie Mouhayar, M.D.
The University of Texas MD Anderson Cancer Center
Houston, TX

9:20-9:40 a.m.

 

 

Cardiotoxicities of novel angiogenesis (VEGF) inhibitors
Javid Moslehi, M.D.
Dana-Farber Cancer Institute
Boston, MA

9:40-9:55 a.m.

 

 

 

 

Gleevec: Selective vs. non-selective TKIs in cardiotoxicity
Jean-Bernard Durand, M.D.
The University of Texas MD Anderson Cancer Center
Houston, TX

Thomas Force, M.D.
Temple University School of Medicine
Philadelphia, PA

9:55-10:05 a.m.

 

 

Case presentation: Dasatinib and pulmonary hypertension
Saamir Hassan, M.D.
The University of Texas MD Anderson Cancer Center
Houston, TX
Break10:05-10:25 a.m.
Session XIII
10:25-10:45


Link between cancer and heart disease: Story of HACE1 and E3 ligase
Peter Liu, M.D. Ph.D.
University of Ottawa Heart Institute
Ottawa, Ontario, Canada
Session XIV
10:45-11:05 a.m.


Cardiac Tumors: Moderator: Jean-Bernard Durand, M.D.
Cardiac Tumors – Diagnosis and Therapy
Monika Leja, M.D.
University of Michigan
Ann Arbor, MI
Session XV
11:05-12:15 a.m.
Clinical Cardiovascular Challenges in a Cancer Center
Moderator: Elie Mouhayar, M.D.
The University of Texas MD Anderson Cancer Center
Houston, TX
11:05-11:20 p.m.Pericardial Effusion
Elie Mouhayar, M.D.
The University of Texas MD Anderson Cancer Center
Houston, TX
11:20-11:35 a.m.Acute Cardiomyopathy
Jean-Bernard Durand, M.D.
The University of Texas MD Anderson Cancer Center
Houston, TX
11:35-11:45 a.m.Radiation and Cardiovascular Implantable Electronic Device
Kaveh Karimzadehnajar, M.D.
The University of Texas MD Anderson Cancer Center
Houston, TX
11:45-12:00 p.m.QT Prolongation and QT induced torsades
Michael Ewer, M.D., J.D., M.P.H and Peter Kim, M.D.
The University of Texas MD Anderson Cancer Center
Houston, TX
12:00-12:15 p.m.Questions & Answers
Lunch12:15-1:00 p.m.
Session XVI
1:00-2:00 p.m
Medical treatment of heart failure
Moderator: Barbara Summers, Ph.D., M.S.N.
Vice President and Chief Nursing Officer
The University of Texas MD Anderson Cancer Center
Houston, TX

1:00-1:15 p.m.

 

Treatment of cancer therapy-induced heart failure
Jean-Bernard Durand, M.D.
The University of Texas MD Anderson Cancer Center
Houston, TX

1:15-1:30 p.m.

 

 

Heart failure in cancer patients: Management through onco-cardiology collaborative
Anecita Fadol, Ph.D., M.S.N.
The University of Texas MD Anderson Cancer Center
Houston, TX

1:30-1:45 p.m.

 

Early diastolic dysfunction precursor to LVEF decline
Giorgio Minotti, M.D.
University Campus Bio-Medico
Rome, Italy
1:45-2:00 p.m.Questions and Answers
Session XVII
2:00-2:30 p.m.
Intervention in cancer patients
Moderator: Saamir Hassan, M.D.
The University of Texas MD Anderson Cancer Center
Houston, TX
2:00-2:15 p.m.Optical coherence tomography
Cezar Iliescu, M.D.
The University of Texas MD Anderson Cancer Center
Houston, TX
2:15-2:30 p.m.Interventional procedures in thrombocytopenic patients
Cezar Iliescu, M.D.
The University of Texas MD Anderson Cancer Center
Houston, TX
Session XVIII
2:30-3:00 p.m.
Advanced heart failure treatment
Moderator: Cezar Iliescu, M.D.
The University of Texas MD Anderson Cancer Center
Houston, TX

2:30-2:45 p.m.

 

 

Advanced heart failure treatment for aging cancer survivors
Igor Gregoric, M.D.
University of Texas Health Science Center
Houston, Texas

2:45-3:00 p.m.

 

 

 

 

 

 

Questions and Answers
Jean-Bernard Durand, M.D.
The University of Texas MD Anderson Cancer Center
Houston, TX

Igor Gregoric, M.D.
University of Texas Health Science Center
Houston, Texas

Guilherme Oliveira, M.D.
Cleveland Clinic
Cleveland, OH
Session XIX
3:00-3:50 p.m.
Clinical trials & research considerations
Moderator: Giorgio Minotti, M.D.
University Campus Bio-Medico
Rome, Italy

3:00-3:15 p.m.

 

 

Assessment of cardiotoxicity and optimization of cardiac screening in Phase I clinical trials
Apostolia-Maria Tsimberidou, M.D., Ph.D.
The University of Texas M. D. Anderson Cancer Center
Houston, TX

3:15-3:30 p.m.

 

Practice Strategies
Joseph Carver, M.D.
Abramson Cancer Center, University of Pennsylvania
Philadelphia, PA

3:30-3:50 p.m.

 

 

 

 

 

 

 

 

 

 

 

 

 

Panel discussion
Aman Buzdar, M.D.
VP, Clinical Research
The University of Texas MD Anderson Cancer Center
Houston, TX

Giorgio Minotti, M.D.
University Campus Bio-Medico
Rome, Italy

Joseph Carver, M.D.
Abramson Cancer Center, University of Pennsylvania
Philadelphia, PA

Daniela Cardinale, M.D. Ph.D.
European Institute of Oncology
Milano, Italy

Jean-Bernard Durand, M.D.
The University of Texas MD Anderson Cancer Center
Houston, TX

Apostolia-Maria Tsimberidou, M.D., Ph.D.
The University of Texas M. D. Anderson Cancer Center
Houston, TX

Adjourn3:50 p.m.

 
14.25 AMA PRA Category 1 Credits™

The University of Texas MD Anderson Cancer Center is an approved provider of continuing nursing education by the Texas Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.

Nursing contact hours will be awarded. Up to 13.50 contact hours for full attendance at all sessions.

For information contact Amy Heaton: aheaton@mdanderson.org or 713-745-6826.


 

Key to How Chemotherapy Causes Heart Failure

Key to how chemotherapy drug causes heart failure. See News Release

© 2014 The University of Texas MD Anderson Cancer Center